|
|
Office Locations:
|
888 Seventh Avenue, 12th Floor
New York, NY 10106
Phone: 212-651-6380
Fax: 212-651-6379
| | |
|
|
|
- Early
- Expansion
- Growth
- Middle Market
|
|
|
|
Life Sciences & Healthcare
Medical Device
|
|
|
|
Aisling Capital is a leading private equity fund that invests in products, technologies, and global businesses that advance health. In particular, the firm seeks companies with promising products in clinical development, or marketed products or services with growth potential. In many cases, Aisling Capital identifies therapeutic and technological areas of interest and then seeks investment opportunities in the leading companies in the target sector. Aisling Capital typically makes investments in healthcare companies that require $20-50 million or more in new capital. The size of the investment is contingent upon the company's stage of development, funding needs and risk profile. Aisling Capital has raised over $1.8 billion in committed capital across four funds.
|
|
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
